Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 9, 2025

MIRA secures board approval to buy SKNY Pharmaceuticals

US-based firm MIRA Pharmaceuticals has secured approval from its board of directors to acquire SKNY Pharmaceuticals, a company engaged in the development of SKNY-1 oral drug candidate for weight loss and smoking cessation.

MIRA develops treatments for neuropsychiatric, neurological, as well as metabolic disorders. Credit: Robina Weermeijer on Unsplash.